Small Forms, Big Consequences: FDA’s Draft Q&A on Orange Book Patent Forms 3542 and 3542a

There is a particular kind of legal document that practitioners tend to underestimate: the administrative form. It looks like paperwork. It feels like paperwork. Then a checkbox left blank, a use code described too broadly, or a signature placed in the wrong field quietly changes the competitive posture of a product for months or years.

That is the territory FDA’s Center for Drug Evaluation and Research stepped into with its June 2026 draft guidance, Forms FDA 3542a and FDA 3542: Questions and Answers. The guidance is not a new rule, and FDA is careful to say that, when finalized, it will reflect the Agency’s current thinking rather than bind FDA or the public. But that is exactly why it is useful: it translates the dense regulatory architecture of Orange Book patent listing into a practical roadmap for the two forms that move patent information into the U.S. drug-approval system.

For a global readership used to very different patent-regulatory interfaces, the U.S. system deserves close attention because it links patent information to generic and 505(b)(2) approval mechanics. Getting these forms right is not clerical hygiene. It is the operational layer of Hatch-Waxman strategy.

Why these forms matter

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), an NDA applicant or holder must submit patent information for each patent for which an infringement claim could reasonably be asserted against an unlicensed manufacturer, user, or seller of the drug, and that either claims the drug substance or drug product, or claims a method of using the drug for which approval is sought or has been granted. For method-of-use patents, the statute and FDA’s regulations make the approval nexus central: a method-of-use patent is filed only if it claims an approved, or pending, method of use in the application.

FDA then publishes the required patent information in Approved Drug Products with Therapeutic Equivalence Evaluations, better known as the Orange Book. That publication is not merely informational. It supplies the patent list against which ANDA and 505(b)(2) applicants must make certifications, including Paragraph IV certifications asserting that a listed patent is invalid, unenforceable, or not infringed.

The strategic consequence is familiar but worth stating precisely. If a listed patent is challenged through a Paragraph IV certification and the NDA holder timely sues, FDA approval of the follow-on application may be stayed for up to 30 months. A patent that is not listed may still be asserted in ordinary patent litigation, but the Orange Book certification and 30-month-stay machinery does not attach to that unlisted patent.

Two forms do the carrying:

• Form FDA 3542a - Patent Information Submitted With the Filing of an NDA, Amendment, or Supplement - is used by an NDA applicant for a patent tied to an unapproved original NDA, amendment, or supplement.

• Form FDA 3542 - Patent Information Submitted Upon and After Approval of an NDA or Supplement - is used by an NDA holder for a patent tied to an approved NDA or approved supplement. This is the form from which FDA publishes certain patent information in the Orange Book.

A useful shorthand: 3542a travels with the pre-approval application record; 3542 is the post-approval Orange Book form.

The timing rules, as a working calendar

Much of the risk in this area is calendar risk. The draft guidance gathers the key deadlines in one place and adds several procedural clarifications that are easy to miss in practice.

• Form 3542a with the original NDA. Patent information submitted on Form 3542a must be filed with the original NDA. If a patent issues after the NDA is filed but before approval, the applicant must submit the information by amendment within 30 days of issuance.

• Form 3542 after approval. For Orange Book listing, the NDA holder must submit Form 3542 no later than 30 days after approval of the NDA or NDA supplement.

• Later-issued patents. If a qualifying patent issues after approval, the NDA holder must submit Form 3542 within 30 days of the patent’s issuance date.

• FDA deficiency notice. If FDA identifies errors or omissions in a timely filed Form 3542, the holder has 15 days after FDA’s notification to submit an acceptable form. The guidance confirms that these are 15 calendar days, not business days.

• Use-code amendments. An amendment to the description of the approved method of use is timely only if filed within 30 days of patent issuance, within 30 days of approval of a corresponding labeling change, or within 30 days of a court or USPTO decision specific to the patent that alters construction of a method-of-use claim. A copy of the decision must accompany the amendment when applicable.

Miss a window and the consequences are not abstract. A late or incomplete patent-information submission can fall outside the framework that makes the Orange Book listing useful in the first place.

Scope: listability starts with the claim

The draft guidance is a concise refresher on the basic listability screen. It does not invite applicants to list every patent adjacent to a product; it reinforces the claim-by-claim connection between the patent and the drug, drug product, or approved method of use.

• Drug substance patents. Submit information only for patents claiming the drug substance that is the subject of the pending or approved NDA, or the same active ingredient.

• Polymorph patents. If a patent claims only a polymorph of the same active ingredient and has no other listing basis, the applicant or holder must certify in the declaration that it has test data showing that the polymorph-containing product will perform the same as the drug product described in the NDA.

• Drug product patents. Submit information only for patents claiming the drug product described in the pending or approved NDA.

• Method-of-use patents. Submit information only for patents claiming indications or other conditions of use for which approval is sought or has been granted. Each pending or approved method of use and its related claim or claims must be identified separately.

• Use codes. For approved NDAs, the holder must provide a description of each patented approved method of use. If the patent does not cover the entire indication or condition of use, the use code should describe only the specific approved method claimed by the patent.

• Unissued patents. Do not submit information on patents before they issue from the USPTO.

One practical detail deserves emphasis. If the patent claims only a method of use, and not the drug substance or drug product, the applicant or holder should leave the drug-substance and drug-product sections blank rather than checking the “No” boxes. That small instruction is exactly the kind of point that prevents avoidable deficiency cycles.

Who can prepare, who can sign, and who can submit

A recurring theme across the Q&A is the difference between preparing or signing a form and submitting it to FDA. The distinction matters in licensing, co-development, acquisition, and royalty arrangements where the patent owner may not be the NDA applicant or holder.

• Preparation and signature are broad. Forms 3542a and 3542 may be completed and signed by the NDA applicant, the NDA holder, the patent owner, or their attorneys, agents, representatives, or other authorized officials. A patent owner that is not the applicant or holder may sign the Section 6 declaration certification.

• Submission authority is narrow. Only the NDA applicant or NDA holder can submit the form to FDA under the NDA. A patent owner that completes the form must route it back to the applicant or holder for submission.

• One patent per form. Each patent needs its own Form 3542a or Form 3542. Do not consolidate multiple patents into one form.

• Foreign parties need a U.S. notice contact. If the applicant, holder, or patent owner has no U.S. residence or place of business, the form must identify a U.S. agent or representative authorized to receive notice of patent certification.

• Section 6 contact information matters. The contact information at the end of Section 6 must correspond to the person signing in field 6.2. FDA says the form will be incomplete if that information is missing.

For deal teams, the lesson is simple: assign Orange Book form responsibility before patent issuance dates start the clock. The entity that owns the patent may not be the entity with authority to submit the form.

Submission mechanics: the right form through the right door

The draft guidance also reads like a checklist for avoiding purely procedural failures. These points are not glamorous, but they are often where a timely filing is won or lost.

• Use the current form. FDA generally will not accept an expired Form 3542a or 3542 if a newer version is available. But if the most current form posted on FDA’s site has itself reached its expiration date and no replacement is posted, continue using the posted version until FDA makes a newer one available.

• Electronic signature and electronic submission only. The forms must be signed electronically and submitted in the electronic format specified by FDA. No wet-ink signatures and no hard-copy submissions.

• Signing is not submission. Electronically signing the form does not send it to FDA. The signed PDF must be saved and submitted to the NDA with Form FDA 356h. FDA recommends including “3542” or “3542a” in the file name.

• Do not attach the patent. FDA says applicants and holders do not need to submit a copy of the patent with Form 3542a or 3542.

• Submit through the official channel. Forms must be submitted under the NDA via the CDER Central Document Room through the Electronic Submissions Gateway. They should not be sent directly to FDA divisions, including Orange Book staff, and courtesy copies by fax, email, or mail should not be submitted.

• Do not rely on courtesy copies for timeliness. FDA says Orange Book staff intend to rely only on submissions received through the official CDER Central Document Room/Electronic Submissions Gateway pathway. For timeliness, FDA looks to the earlier of the Central Document Room date-stamp or official receipt in a compliant electronic submission.

• Incomplete Form 3542 submissions can be salvaged only quickly. If a timely Form 3542 is incomplete or shows the patent is not eligible for listing, the holder must submit an acceptable form, complete and showing eligibility, within 15 calendar days of FDA’s notification to preserve the original submission date.

Use codes deserve their own review meeting

Use codes are short descriptions of patented approved methods of use, but their brevity should not fool anyone. They are central to how follow-on applicants assess whether they can submit a section viii statement and carve protected uses out of proposed labeling, or whether they must make a Paragraph IV certification.

The draft guidance gives use-code mechanics unusually practical attention:

• Adding a use code. Use the current Form 3542, check “yes” in field 1.g, and follow the field 1.h instructions.

• Changing a use code is not the same as removing one. FDA will not treat a modification of an existing use code as a removal unless the holder expressly states that intent.

• Removing a use code. State the intent to remove the use code in field 1.h and in the cover letter. Do both. FDA will not infer removal from silence.

• Align the code to the patented approved method. If the patent does not claim the entire approved indication or condition of use, the use code should be no broader than the specific approved method that the patent actually claims.

• Account for 180-day exclusivity. Even after a delisting or removal request, patent information, including use codes, may remain listed until FDA determines that no first applicant is eligible for 180-day exclusivity based on a Paragraph IV certification to that patent, or until that exclusivity has expired or been extinguished.

Why does this matter? An overbroad use code can make a lawful carve-out look unavailable and push a follow-on applicant toward a Paragraph IV certification it might not otherwise need. An incompletely removed use code can keep a barrier in place after the patent rationale has disappeared. These are not formatting choices; they are competition-shaping choices made through a text box.

FDA’s common deficiencies are a ready-made checklist

The draft guidance closes with a valuable list of common deficiencies in Form 3542 submissions. For internal review, this list should become a pre-submission checklist:

1.     Field 1 - U.S. agent. Do not forget the U.S. agent where the patent owner or NDA holder is outside the United States. If the same agent represents both, use the “Both” designation. If different agents represent different parties, field 1.f should list both agents by using the “Add Section 1.f” button and have checked the appropriate box to specify whether that agent represents the patent owner or NDA holder.

2.    Field 1.h - use-code changes. Clearly explain all changes to a listed use code. If the holder intends to remove an existing use code, that intent must be explicit in both field 1.h and the cover letter.

3. Field 4.2a - labeling subsections. Identify the specific subsections of approved labeling that describe the patented method of use. If there are no applicable subsections, insert “subsection N/A.”

4. Field 4.2b - existing use codes. If relying on an existing use code upon supplement approval, submit a use code that is identical to the use code already published in the Orange Book unless a change is actually sought.

For in-house teams and outside counsel alike, building these points into the form-review template is a no-cost risk reduction.

Reissued patents, discontinued products, and other edge cases

Several of the Q&As are easy to overlook but valuable in practice:

• Reissued patents. If reissuance means the original patent or a claim no longer meets the statutory listing criteria, for example, because the original patent was surrendered on reissuance, the holder must promptly notify FDA to amend or withdraw the patent information and request removal from the Orange Book. But both the original and reissued patent may appear for a time if first-applicant 180-day exclusivity is tied to a Paragraph IV certification to the original patent.

• Discontinued marketing is not the same as withdrawn approval. If a holder stops marketing a drug product for business reasons but has not requested withdrawal of the NDA approval, the holder must continue to comply with patent-listing requirements, including for newly issued patents that claim the discontinued approved product.

• Corrections and changes must use the form. Corrections or changes to listed patent information generally must be submitted on the current Form 3542 by checking “yes” in field 1.g and explaining the change in field 1.h. FDA says it will not accept corrections or changes unless they are submitted on the appropriate forms, subject to the separate rule allowing a withdrawal or request to remove a patent by letter.

The bigger picture: precision under a microscope

It would be a mistake to read the draft guidance in isolation. It lands in the middle of the most sustained scrutiny of Orange Book listing practice in years.

Since its September 2023 policy statement (FTC, Statement Concerning Brand Drug Manufacturers’ Improper Listing of Patents in the Orange Book (Sept. 14, 2023), the Federal Trade Commission has treated improper Orange Book listings as potential unfair methods of competition under Section 5 of the FTC Act. The agency then used FDA’s patent-listing dispute process to challenge more than 100 listings in November 2023, more than 300 listings across 20 brand-name products in April 2024, and more than 200 listings across 17 brand-name products in May 2025. In December 2025, the FTC announced that Teva had requested removal of more than 200 Orange Book patent listings following the agency’s challenges.

The courts have sharpened the picture as well. In Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC, 124 F.4th 898 (Fed. Cir. 2024), the Federal Circuit affirmed a delisting order for Teva asthma-inhaler patents directed to device components such as dose counters and canisters where the patents did not claim the active ingredient, albuterol sulfate. For drug-device combinations, the message is no longer theoretical: device-adjacent innovation does not automatically belong in the Orange Book unless the patent satisfies the statutory listing criteria.

The throughline is clear. FDA’s Orange Book role remains largely ministerial; the applicant or holder is responsible for the substantive listing judgment and the procedural accuracy of the form. The listability decision and the form mechanics are therefore not separate problems. They are two sides of the same certification risk.

Practical takeaways

For teams managing U.S. listings, and for global teams coordinating patent-regulatory strategy across jurisdictions, several action items follow naturally:

• Treat the form as a substantive legal instrument. A completed Form 3542 or 3542a is not administrative overhead. It is a certified submission that feeds a competition-sensitive public record.

• Pair patent docketing with regulatory docketing. Patent issuance, NDA approval, supplement approval, labeling changes, court decisions, and USPTO decisions should all trigger Orange Book review workflows.

• Prepare a claim-by-claim listability memo before the form is filled. The form should reflect an already-reasoned conclusion about why each patent qualifies as a drug-substance, drug-product, or method-of-use patent.

• Audit use codes against both claims and labeling. Confirm that each use code maps to the specific patented approved method and that intended removals were made in field 1.h and in the cover letter.

• Pressure-test drug-device combination listings after Teva v. Amneal. A device-component patent that does not claim the active ingredient is a litigation and enforcement target, not a routine Orange Book candidate.

• Clarify filing authority in license and collaboration agreements. Patent owners can prepare and sign in some circumstances, but only NDA applicants and holders can submit under the NDA.

• Build FDA’s deficiency list into the template. U.S.-agent designations, use-code explanations, labeling subsections, and exact-match existing use codes should be mandatory review fields.

What happens next

This remains a draft guidance. FDA is accepting comments on Docket No. FDA-2026-D-2698, and the Federal Register notice gives August 14, 2026 as the date for submitting comments to ensure FDA considers them before beginning work on the final guidance. That creates a real opportunity for practitioners who routinely wrestle with these forms - especially on use-code mechanics, foreign-party signatures, electronic-submission logistics, and the interaction between form deficiencies and Orange Book publication timing.

Ambiguities resolved during the comment process are ambiguities that may not need to be litigated later.

 This post was written by Lisa Mueller.